<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01750541</url>
  </required_header>
  <id_info>
    <org_study_id>SB-021</org_study_id>
    <secondary_id>MOH-021</secondary_id>
    <nct_id>NCT01750541</nct_id>
  </id_info>
  <brief_title>Haloperidol vs. Valproate in Agitation</brief_title>
  <official_title>Haloperidol vs. Valproate in the Management of Agitated Patients Presenting to the Emergency Department: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the efficacy of haloperidol and valproate in management
      of people with agitation in emergency department
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Agitated Behavior Scale (ABS) score</measure>
    <time_frame>within the first 30 minutes of treatment onset</time_frame>
    <description>Patients were rated before medication administration and within 30 minutes afterwards according to Agitated Behavior Scale (ABS) score. Any statistically significant change in ABS score consider as positive effect of either intervention.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Psychomotor Agitation</condition>
  <arm_group>
    <arm_group_label>Haloperidol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Haloperidol 5mg intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valproate single Infusion; 400 mg (weigh&lt;60 kg), 500 mg (weight&gt;60 Kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <arm_group_label>Haloperidol</arm_group_label>
    <other_name>Haldol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproate</intervention_name>
    <arm_group_label>Valproate</arm_group_label>
    <other_name>Depakene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of psychomotor agitation

          -  aged 18 to 65 years

        Exclusion Criteria:

          -  Pregnant patients

          -  Severe liver disease

          -  History of drug (haloperidol/valproate) allergy

          -  Readily amendable causes for the agitation (hypoxemia or hypoglycemia)

          -  Hypotension (systolic blood pressure (SBP) â‰¤ 90 mm Hg)

          -  Known history of liver disease or uncontrolled diabetes

          -  Noticeable or suspected head trauma

          -  Previous history of neuroleptic malignant syndrome

          -  Receiving psychotropic medication, neuroleptic agents or cholinesterase inhibitors at
             the time of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamran Heydari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Emergency Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Emergency Medicine, Imam Hossein Hospital</name>
      <address>
        <city>Tehran</city>
        <zip>1617763141</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2012</study_first_submitted>
  <study_first_submitted_qc>December 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <last_update_submitted>January 5, 2013</last_update_submitted>
  <last_update_submitted_qc>January 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Dr. Kamran Heydari</investigator_full_name>
    <investigator_title>Assistant Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 7, 2013</submitted>
    <returned>February 7, 2013</returned>
    <submitted>February 17, 2013</submitted>
    <returned>March 20, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

